Article by Fabio D Almeida1, Chi-Kwan Yen1, Mark C Scholz2, Richard Y Lam2, Jeffrey Turner2, Larry L Bans3, Robert Lipson3
Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer.
Read or download the report from here
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Read more on fda.gov